P-330 the Third-Generation Genetic Engineered Mouse Model of Late-Stage Multiple Myeloma

reached).Grade 3-4 hematologic AEs included neutropenia (64%) and thrombocytopenia (20%).Febrile neutropenia occurred in 5%.Non hematologic AEs (all; grade 3-4) included infections (66%; 7%); fatigue (48%; 7%); dyspnea (41%; 2%); increase in ALT/ AST (34%; 11%); heart failure or reduced ejection fraction (7%; 0%).There were no hospitalizations or deaths from COVID19.Conclusions: Dara wKPd shows some of the highest response rates (98%) and median PFS (30.9 months) in relapsed/refractory MM.This highlights the efficacy of 4-drug regimens and builds on the established activity of dara, K, and P, with manageable toxicity and convenience of weekly K.